Developer docs
API playgroundTry for free, no card

Search company profiles

Enthea

Full company profile

uuid0008xvq

Namestring
Enthea
Websiteurl
enthea.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Enthea is a U.S.-based, venture-backed insurance provider founded in 2019 and headquartered in Newton, Massachusetts. The company designs and distributes employer and union benefit plans that cover psychedelic-assisted therapy, with its initial product focused on Ketamine-Assisted Therapy (KAT). KAT is positioned as a complement to traditional mental health treatment—talk therapy, SSRIs/SNRIs, and lifestyle interventions—and is targeted at treatment-resistant depression, anxiety, and PTSD populations where conventional approaches have produced partial or no response.

The core technical premise is pharmacological rather than digital: ketamine targets NMDA receptors, promotes glutamate release, and is claimed to drive neuroplasticity and rapid symptom relief (often within hours or days of a session), versus the multi-week onset of SSRIs. Enthea's own intellectual property layer is the insurance product and provider network, not the molecule. Disclosed outcomes include a 67% improvement rate in major depressive disorder among Enthea users and 50-70% improvement in treatment-resistant depression patients more broadly, alongside a stated roadmap to cover MDMA- and psilocybin-assisted therapy contingent on FDA approvals.

Enthea operates a B2B enterprise field-sales model, signing employer and union clients directly and delivering care through a curated network of licensed ketamine providers across planned 40 U.S. markets. Revenue is structured as recurring employer-paid insurance premiums, while the underlying KAT unit economics ($400-$800 per session, $2,000-$4,000 per full course) sit with provider partners. As of the most recent data, the company had raised a single $2 million seed round in December 2022 led by Tabula Rasa Ventures (with Mystic Ventures participating) and had not disclosed revenue, ARR, or unit-pricing for its benefit plans. One named enterprise customer, Dr. Bronner's, appears in published case material.

Short descriptiontext

Enthea is a U.S. insurance provider that offers employers and unions benefit plans covering psychedelic-assisted therapy, initially Ketamine-Assisted Therapy, with planned expansion to MDMA and psilocybin coverage subject to regulatory approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
psychedelic-assisted therapy, ketamine insurance coverage, employee mental health benefits, treatment-resistant depression care, workplace wellness insurance
Industry2 codes
PRIMARYFSAIAMAB
Worksite Hospital Indemnity Insurance
Financial & Insurance/Insurance — Life & Health/Supplemental & Voluntary Benefits (Worksite)
SECONDARYFSAIAKAF
Voluntary/Worksite Critical Illness & Hospital Indemnity (Employee-Paid)
Financial & Insurance/Insurance — Life & Health/Critical Illness & Hospital Indemnity Insurance
NAICS code1 code
  • Direct Health and Medical Insurance Carriers524114
SIC code1 code
  • Hospital & Medical Service Plans6324
Product category
Employee Health Benefits Insurance
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Insurance Premiums from Employers
TypeSubscription Recurring
Description

Enthea provides insurance plans for psychedelic healthcare, charging employers premiums to include ketamine-assisted therapy as a workplace benefit. The company signed several clients with plans to add more, expecting significant employer funding.

hitconsultant.net
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Ketamine-Assisted Therapy (KAT) per session
ModelUnit PricingBilling cadencePay-as-you-go
Notes

A single ketamine therapy session can range from $400 to $800, while a full course of treatment typically costs between $2,000 and $4,000. Insurance coverage varies by provider, diagnosis, and state regulations.

enthea.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Enthea provides insurance plans that cover psychedelic-assisted therapy, primarily Ketamine-Assisted Therapy (KAT), as an employee workplace benefit for employers and unions. The company operates a national provider network of licensed ketamine therapy practitioners across U.S. markets, enabling covered employees and union members to access treatment for treatment-resistant depression, anxiety, and PTSD. Initial coverage focuses on ketamine, with planned future expansion to MDMA and psilocybin therapies pending regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 67% improvement rate for major depressive disorder conditions
+2 more records
Product overview1 text field

Enthea offers a suite of insurance products for psychedelic healthcare, with its primary offering being insurance coverage for Ketamine-Assisted Therapy (KAT). The company operates a provider network connecting patients with licensed psychedelic therapy practitioners, and offers employer workplace benefits and union mental health plans. The core product portfolio includes KAT insurance coverage, a psychedelic healthcare provider network, and employer/union benefit packages, with planned future expansion to cover MDMA and psilocybin therapies pending regulatory approval.

Product and service4 records
1Ketamine-Assisted Therapy (KAT) Insurance Coverage
CategoryHealth insurance product
Description

Insurance plans that cover ketamine-assisted psychotherapy as a workplace benefit, providing coverage for treatment-resistant depression, anxiety, PTSD, and other mental health conditions for employees of subscribing employers and union members.

2Psychedelic Healthcare Provider Network
CategoryProvider network service
Description

Network of licensed healthcare providers offering psychedelic-assisted therapy services, accessible through Enthea's insurance plans for covered employees across U.S. markets.

3Employer Workplace Benefits Plan
CategoryEmployer benefits plan
Description

Insurance product packaged for employers to include psychedelic-assisted therapy coverage as part of their employee workplace benefits, targeting behavioral health conditions including treatment-resistant depression, anxiety, and PTSD.

4Union Mental Health Benefits Plan
CategoryUnion benefits plan
Description

Insurance plans specifically designed for labor unions to provide psychedelic-assisted therapy benefits to their members as part of union-negotiated health benefits.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Modern Health delivers global mental health benefits to employers through a network of coaches and therapists. It competes for the same employer benefits dollar and could expand into ketamine or psychedelic coverage as clinical evidence matures.

TypeEmerging player
Description

Mindbloom provides at-home ketamine-assisted therapy protocols, supplying clinical services rather than insurance. It overlaps with Enthea on the demand side for KAT and could become a network provider or a competing coverage enabler.

TypeDirect peer
Description

Spring Health sells precision mental health benefits to employers covering therapy, coaching, and medication. It is a direct competitor in the employer-sponsored mental health benefits category and a likely bundler of psychedelic coverage once approved.

TypeEmerging player
Description

Numinus operates psychedelic-assisted therapy clinics and research infrastructure. It overlaps with Enthea as both a potential provider-network partner and a competing clinical delivery channel for insured members.

TypeDirect peer
Description

Lyra provides mental health benefit plans to employers, including therapy, coaching, and medication management. It competes directly with Enthea for employer mental-health benefit spend and represents the incumbent Enthea must displace in HR buying decisions.

TypeEmerging player
Description

Compass Pathways is developing psilocybin therapy for treatment-resistant depression. Its clinical progress directly impacts Enthea's planned psilocybin coverage line and represents a critical therapeutic pipeline dependency.

TypeDirect peer
Description

Cerebral provides online mental health treatment including medication management and has explored ketamine services. It competes with Enthea for employer mental health spend and for the ketamine-assisted therapy patient pool.

8ATAI Life Sciences
TypeEmerging player
Description

ATAI is a clinical-stage biopharma platform investing in psychedelic mental health therapies including psilocybin, MDMA, and DMT programs. It is a therapeutic counterparty whose pipeline success or failure shapes Enthea's product roadmap.

TypeBroad incumbent
Description

Evernorth, the health services arm of Cigna, administers behavioral health benefits for millions of insured members. It represents the type of incumbent payer Enthea must partner with or compete against as psychedelic coverage normalizes.

TypeBroad incumbent
Description

Headspace Health (the merged Headspace and Ginger entity) offers employer mental health benefits covering therapy, coaching, and self-guided content. It is a broader incumbent in the employer mental health benefits category where Enthea is trying to insert psychedelic coverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enthea

Employee Health Benefits Insuranceenthea.com

Enthea is a U.S. insurance provider that offers employers and unions benefit plans covering psychedelic-assisted therapy, initially Ketamine-Assisted Therapy, with planned expansion to MDMA and psilocybin coverage subject to regulatory approval.

What Enthea does

Enthea is a U.S.-based, venture-backed insurance provider founded in 2019 and headquartered in Newton, Massachusetts. The company designs and distributes employer and union benefit plans that cover psychedelic-assisted therapy, with its initial product focused on Ketamine-Assisted Therapy (KAT). KAT is positioned as a complement to traditional mental health treatment—talk therapy, SSRIs/SNRIs, and lifestyle interventions—and is targeted at treatment-resistant depression, anxiety, and PTSD populations where conventional approaches have produced partial or no response.

The core technical premise is pharmacological rather than digital: ketamine targets NMDA receptors, promotes glutamate release, and is claimed to drive neuroplasticity and rapid symptom relief (often within hours or days of a session), versus the multi-week onset of SSRIs. Enthea's own intellectual property layer is the insurance product and provider network, not the molecule. Disclosed outcomes include a 67% improvement rate in major depressive disorder among Enthea users and 50-70% improvement in treatment-resistant depression patients more broadly, alongside a stated roadmap to cover MDMA- and psilocybin-assisted therapy contingent on FDA approvals.

Enthea operates a B2B enterprise field-sales model, signing employer and union clients directly and delivering care through a curated network of licensed ketamine providers across planned 40 U.S. markets. Revenue is structured as recurring employer-paid insurance premiums, while the underlying KAT unit economics ($400-$800 per session, $2,000-$4,000 per full course) sit with provider partners. As of the most recent data, the company had raised a single $2 million seed round in December 2022 led by Tabula Rasa Ventures (with Mystic Ventures participating) and had not disclosed revenue, ARR, or unit-pricing for its benefit plans. One named enterprise customer, Dr. Bronner's, appears in published case material.

Enthea firmographics

Firmographics
Name
Enthea
Website
https://enthea.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Enthea is a U.S. insurance provider that offers employers and unions benefit plans covering psychedelic-assisted therapy, initially Ketamine-Assisted Therapy, with planned expansion to MDMA and psilocybin coverage subject to regulatory approval.
Ownership category
akta.pro rank

Enthea industry classification

Industry
Product category
Employee Health Benefits Insurance
NAICS
Direct Health and Medical Insurance Carriers (524114)
SIC
Hospital & Medical Service Plans (6324)
akta.pro industry
PRIMARYFSAIAMAB
Worksite Hospital Indemnity Insurance
Financial & Insurance/Insurance — Life & Health/Supplemental & Voluntary Benefits (Worksite)
SECONDARYFSAIAKAF
Voluntary/Worksite Critical Illness & Hospital Indemnity (Employee-Paid)
Financial & Insurance/Insurance — Life & Health/Critical Illness & Hospital Indemnity Insurance

Keywords

  • Psychedelic-assisted therapy
  • Ketamine insurance coverage
  • Employee mental health benefits
  • Treatment-resistant depression care
  • Workplace wellness insurance

Where Enthea is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Enthea business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Insurance Premiums from Employers: Enthea provides insurance plans for psychedelic healthcare, charging employers premiums to include ketamine-assisted therapy as a workplace benefit. The company signed several clients with plans to add more, expecting significant employer funding.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goKetamine-Assisted Therapy (KAT) per session

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Enthea product offering

Product offering

Core offering

Enthea provides insurance plans that cover psychedelic-assisted therapy, primarily Ketamine-Assisted Therapy (KAT), as an employee workplace benefit for employers and unions. The company operates a national provider network of licensed ketamine therapy practitioners across U.S. markets, enabling covered employees and union members to access treatment for treatment-resistant depression, anxiety, and PTSD. Initial coverage focuses on ketamine, with planned future expansion to MDMA and psilocybin therapies pending regulatory approval.

Product overview

Enthea offers a suite of insurance products for psychedelic healthcare, with its primary offering being insurance coverage for Ketamine-Assisted Therapy (KAT). The company operates a provider network connecting patients with licensed psychedelic therapy practitioners, and offers employer workplace benefits and union mental health plans. The core product portfolio includes KAT insurance coverage, a psychedelic healthcare provider network, and employer/union benefit packages, with planned future expansion to cover MDMA and psilocybin therapies pending regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ketamine-Assisted Therapy (KAT) Insurance Coverage Insurance plans that cover ketamine-assisted psychotherapy as a workplace benefit, providing coverage for treatment-resistant depression, anxiety, PTSD, and other mental health conditions for employees of subscribing employers and union members.
  • Psychedelic Healthcare Provider Network Network of licensed healthcare providers offering psychedelic-assisted therapy services, accessible through Enthea's insurance plans for covered employees across U.S. markets.
  • Employer Workplace Benefits Plan Insurance product packaged for employers to include psychedelic-assisted therapy coverage as part of their employee workplace benefits, targeting behavioral health conditions including treatment-resistant depression, anxiety, and PTSD.
  • Union Mental Health Benefits Plan Insurance plans specifically designed for labor unions to provide psychedelic-assisted therapy benefits to their members as part of union-negotiated health benefits.

Quantifiable outcome

  • 67% improvement rate for major depressive disorder conditions
  • +2 more outcomes

Companies that use Enthea

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Enthea technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Enthea partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Enthea competitors and assessment

Company assessment

Direct peers

  • Modern Health: Modern Health delivers global mental health benefits to employers through a network of coaches and therapists. It competes for the same employer benefits dollar and could expand into ketamine or psychedelic coverage as clinical evidence matures.
  • Spring Health: Spring Health sells precision mental health benefits to employers covering therapy, coaching, and medication. It is a direct competitor in the employer-sponsored mental health benefits category and a likely bundler of psychedelic coverage once approved.
  • Lyra Health: Lyra provides mental health benefit plans to employers, including therapy, coaching, and medication management. It competes directly with Enthea for employer mental-health benefit spend and represents the incumbent Enthea must displace in HR buying decisions.
  • Cerebral: Cerebral provides online mental health treatment including medication management and has explored ketamine services. It competes with Enthea for employer mental health spend and for the ketamine-assisted therapy patient pool.

Emerging players

  • Mindbloom: Mindbloom provides at-home ketamine-assisted therapy protocols, supplying clinical services rather than insurance. It overlaps with Enthea on the demand side for KAT and could become a network provider or a competing coverage enabler.
  • Numinus Wellness: Numinus operates psychedelic-assisted therapy clinics and research infrastructure. It overlaps with Enthea as both a potential provider-network partner and a competing clinical delivery channel for insured members.
  • Compass Pathways: Compass Pathways is developing psilocybin therapy for treatment-resistant depression. Its clinical progress directly impacts Enthea's planned psilocybin coverage line and represents a critical therapeutic pipeline dependency.
  • ATAI Life Sciences: ATAI is a clinical-stage biopharma platform investing in psychedelic mental health therapies including psilocybin, MDMA, and DMT programs. It is a therapeutic counterparty whose pipeline success or failure shapes Enthea's product roadmap.

Broad incumbents

  • Evernorth (Cigna): Evernorth, the health services arm of Cigna, administers behavioral health benefits for millions of insured members. It represents the type of incumbent payer Enthea must partner with or compete against as psychedelic coverage normalizes.
  • Headspace Health: Headspace Health (the merged Headspace and Ginger entity) offers employer mental health benefits covering therapy, coaching, and self-guided content. It is a broader incumbent in the employer mental health benefits category where Enthea is trying to insert psychedelic coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Enthea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enthea leadership team

Management profile

Number of profiles

Enthea funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enthea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enthea

What does Enthea do?

Enthea provides insurance plans that cover psychedelic-assisted therapy, primarily Ketamine-Assisted Therapy (KAT), as an employee workplace benefit for employers and unions. The company operates a national provider network of licensed ketamine therapy practitioners across U.S. markets, enabling covered employees and union members to access treatment for treatment-resistant depression, anxiety, and PTSD. Initial coverage focuses on ketamine, with planned future expansion to MDMA and psilocybin therapies pending regulatory approval.

Is Enthea a public or private company?

Enthea is a private company. It is classified as venture growth investor backed and is currently operating.

When was Enthea founded?

Enthea was founded in 2019. It employs 11 to 50 people.

Where is Enthea based?

Enthea is headquartered in Boston, United States, in the North America region.

How does Enthea make money?

One revenue line is on record: insurance Premiums from Employers.

Who are Enthea's main competitors?

Direct peers on record are Modern Health, Spring Health, Lyra Health and Cerebral. Emerging players are Mindbloom, Numinus Wellness, Compass Pathways and ATAI Life Sciences. Broad incumbents are Evernorth (Cigna) and Headspace Health.

Does Enthea have an API?

No public API is recorded for Enthea.

What industry is Enthea in?

Enthea's product category is Employee Health Benefits Insurance. Its primary akta.pro industry code is FSAIAMAB, Worksite Hospital Indemnity Insurance, with a secondary code of FSAIAKAF, Voluntary/Worksite Critical Illness & Hospital Indemnity (Employee-Paid). Its NAICS code is 524114 and its SIC code is 6324.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BhbusinessWhat’s Behind Uneven Adoption of Collaborative Care CodesProvider adoption of psychiatric collaborative care management codes remains low eight years after introduction, driven by billing and operational complexity. A 2021 study showed an eightfold increase in use but noted denied services as a barrier, and payer coverage remains fragmented. Experts suggest value-based care arrangements could ease adoption.Global Wellness SummitEnthea announces US rollout in 2023 to offer psychedelic therapy as a workplace benefitEnthea, a provider of insurance plans for psychedelic healthcare, has raised a $2 million seed round led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups. The funds will be used to launch services into 40 markets across the United States in 2023. This represents a notable development in the emerging psychedelic therapy workplace benefits space as the industry seeks to expand access to these treatments through employer-sponsored plans.BhbusinessFrom Experimental to Mainstream: TMS, Ketamine and Psychedelic FrontiersThe demand for behavioral health services has led to a significant increase in the adoption of interventional psychiatry treatments, notably Transcranial Magnetic Stimulation (TMS) and ketamine therapy. Sherry Rais, CEO of Enthea, reported a 6,000% increase in employer interest in TMS over the past year, highlighting a shift towards more effective treatment options for mental health conditions. The article discusses the potential for these therapies to become mainstream given subsequent changes in reimbursement and regulatory frameworks.Willamette WeekBend Psilocybin Center Becomes First in Oregon to Offer Insurance CoverageBendable Therapy, a Bend-based psilocybin service center, became the first in Oregon to accept private insurance through Enthea. The nonprofit has served over 200 clients and provided more than $275,000 in financial aid. The partnership aims to expand access to psychedelic therapy.https://www.kptv.comPsilocybin center in Bend first to partner with health insurance providerBendable Therapy in Bend, Oregon, partnered with Enthea Insurance to provide first-time private coverage for psilocybin services in the state. The partnership addresses high out-of-pocket costs, which can reach $3,800 per session, and aims to make psychedelic therapy a reimbursable mental health modality.GlobeNewswireEnthea to Present at the 2025 Sequire Investor Summit in Puerto RicoEnthea will present at the Sequire Investor Summit 2025, held Jan 21-23 in San Juan, Puerto Rico. The company highlights its ketamine-assisted therapy and stellate ganglion block, citing an 86% reduction in PTSD symptoms and 80% of members discontinuing antidepressants. It aims to connect with investors for a healthier workforce.YahooOsmind Increases Access to Breakthrough Mental Health Treatments through Partnerships with Enthea and First Tracks HealthOsmind announced partnerships with Enthea and First Tracks Health to expand access to breakthrough mental health treatments. The partnerships connect clinics and patients, including therapies like ketamine-assisted psychotherapy and TMS, for employees of partner employers. Osmind's CEO said the collaborations aim to address insurance coverage barriers.Business Wire BlogOsmind Increases Access to Breakthrough Mental Health Treatments through Partnerships with Enthea and First Tracks HealthOsmind announced partnerships with Enthea and First Tracks Health to expand access to breakthrough mental health treatments. The partnerships connect clinics and patients, including therapies like ketamine-assisted psychotherapy and TMS, for employees whose employers have partnered with these insurers. The collaborations aim to address insurance coverage barriers for over 57 million Americans with mental illness.WsjPsychedelics Paid for by Work? It’s ComingPlexis Healthcare Systems, founded by Jorge Yant, is offering psychedelic-assisted therapy to employees through Enthea, a benefits startup that contracts with providers for discounted rates. The company, which has experimented with psychedelics, sees potential for mental health benefits.HR BrewIs ketamine therapy set to become the next workplace perk?Dr. Bronner's began offering ketamine-assisted therapy to employees last year, with 7% of its health plan participants using it. Enthea, the only licensed provider, expects more employers to adopt the benefit as regulations shift. Traditional insurers may eventually cover it, though MDMA and psilocybin remain federally illegal.